Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
Filamon LTD
Psyence Australia Pty Ltd
ViroMissile, Inc.
Tizona Therapeutics, Inc
Sapience Therapeutics
Daiichi Sankyo
Natera, Inc.
Second Life Therapeutics
Innate Pharma
NeoTX Therapeutics Ltd.
DualityBio Inc.
Massive Bio, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Sensei Biotherapeutics, Inc.
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
Tempus AI
Theratechnologies
Seagen Inc.
Labcorp Corporation of America Holdings, Inc
Agenus Inc.
Taproot Health
Eli Lilly and Company
Vincerx Pharma, Inc.
VitaMed Research LLC
NGM Biopharmaceuticals, Inc
RECORDATI GROUP
Vector Vitale LLC
AstraZeneca
Pfizer
Exelixis
Sanguine Biosciences
NGM Biopharmaceuticals, Inc
Convalife (Shanghai) Co., Ltd.
Klus Pharma Inc.
Kineta Inc.
Namida Lab
Sierra Oncology LLC - a GSK company
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
PACT Pharma, Inc.
Allarity Therapeutics
MacroGenics
MacroGenics
SpeciCare
Lumos Pharma
Celgene